P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

PHASE3RecruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

July 18, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2028

Conditions

Primary MyelofibrosisMyeloproliferative Neoplasm

Interventions

BIOLOGICAL

Ropeginterferon alfa-2b

"Pre-filled Syringe.~Dosage: up to 500mcg"

OTHER

Placebo

Placebo is a look-alike substance with the intervention (Ropeginterferon alfa-2b) that contains no active drug.

Trial Locations (1)

RECRUITING

University of Yamanashi Hospital, Chūō